BRAF and melanoma: In patients with a BRAF V600K mutation, the iORR was 6.7% (1 of 15 patients) in cohort A and 22.2% (4 of 18 patients) in cohort B. Among patients with BRAF V600E-mutated melanoma, the mPFS was about 16 weeks in both groups.